Scarica l'app Stockscreener
0.6944
2.42%
0.0164
Dopo l'orario di chiusura:
.71
0.0156
+2.25%
Precedente Chiudi:
$0.678
Aprire:
$0.6492
Volume 24 ore:
39,786
Relative Volume:
0.01
Capitalizzazione di mercato:
$3.39M
Reddito:
-
Utile/perdita netta:
$-15.19M
Rapporto P/E:
-0.5301
EPS:
-1.31
Flusso di cassa netto:
$-9.85M
1 W Prestazione:
-0.37%
1M Prestazione:
-14.82%
6M Prestazione:
-83.70%
1 anno Prestazione:
-91.32%
Intervallo 1D:
$0.6492
$0.698
Intervallo di 1 settimana:
$0.6301
$0.73
Portata 52W:
$0.4603
$8.997
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Nome
Virpax Pharmaceuticals Inc
Settore
Industria
Telefono
610-727-4597
Indirizzo
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Virpax Pharmaceuticals Inc Borsa (VRPX) Ultime notizie
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Australia
Virpax Pharmaceuticals announces auditor change and board resignation - Investing.com
Virpax Pharmaceuticals Overhauls Leadership and Auditor Amid Concerns - TipRanks
Checking in on Vir Biotechnology Inc (VIR) after recent insiders movement - Knox Daily
Visionstate (CVE:VIS) Trading 25% Higher - Defense World
Investing in Viridian Therapeutics Inc (VRDN) Is Getting More Attractive - Knox Daily
Virpax Pharmaceuticals sees board member departure By Investing.com - Investing.com Canada
Virpax Pharmaceuticals sees board member departure By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals sees board member departure - Investing.com
Virpax Pharmaceuticals sees board member departure By Investing.com - Investing.com Australia
Virpax Pharmaceuticals Announces Key Management Changes - TipRanks
Faruqi & Faruqi Reminds Vicor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire
It makes sense and dollars to buy Viridian Therapeutics Inc (VRDN) stock - SETE News
Virax Biolabs Group Ltd Inc. (VRAX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
A closer look at VRAX’s price-to-free cash flow ratio - US Post News
VRDN (Viridian Therapeutics Inc) has impressive results - US Post News
Virpax Pharmaceuticals Inc (VRPX) is looking forward to a strong quarter - SETE News
Virpax Pharmaceuticals Inc (VRPX)’s Market Momentum: Closing Strong at 0.82, Up 0.99 - The Dwinnex
Can you still get a good price for Virpax Pharmaceuticals Inc (VRPX) Shares at this point? - US Post News
Virpax Pharmaceuticals receives $2.5M loan financing - Pennsylvania Business Report
Virpax Pharmaceuticals Inc (VRPX)’s stock rises to 1.20 per share - US Post News
Virpax Pharmaceuticals Reports Q2 2024 Financial Results and Strategic Progress - MyChesCo
Virpax Pharmaceuticals Inc: Navigating Market Fluctuations with a 5.77M Market Cap - The InvestChronicle
Daily Progress: Virpax Pharmaceuticals Inc (VRPX) Gain 8.12, Closing at 0.92 - The Dwinnex
VRPX (Virpax Pharmaceuticals) Momentum Rank : 2 (As of Aug. 20, 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) 3-Year FCF Growth Rate : -39.90% (As of Jun. 2024) - GuruFocus.com
VRPX (Virpax Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -13.40% (As of Jun. 2024) - GuruFocus.com
Virpax Pharmaceuticals to Present at Sidoti August Virtual Investor Conference - MyChesCo
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Decline in Short Interest - Defense World
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - StockTitan
VRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024 - InvestorPlace
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 - Yahoo Finance
Marinus Pharmaceuticals to Announce Q2 Financial Results - MyChesCo
Virpax Pharmaceuticals Regains Nasdaq Compliance - MSN
Virpax Pharmaceuticals gains compliance extension from Nasdaq - Investing.com India
Virpax Pharmaceuticals gains compliance extension from Nasdaq By Investing.com - Investing.com Australia
Virpax Pharmaceuticals Regains Nasdaq Compliance - MyChesCo
Virpax Pharmaceuticals gains compliance extension from Nasdaq - Investing.com
Virpax Pharmaceuticals Navigates Stock, Governance, and Compliance Challenges - TipRanks
Holdings of Virpax Pharmaceuticals Inc (VRPX) are aligned with the stars - SETE News
Ratio Revelations: Virpax Pharmaceuticals Inc (VRPX)’s Financial Metrics in the Spotlight - The Dwinnex
What was Virpax Pharmaceuticals Inc (VRPX)’s performance in the last session? - US Post News
Virpax Pharmaceuticals Inc: Analyzing VRPX Stock Trends - The InvestChronicle
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com India
Virpax Pharmaceuticals pays off $2.5 million secured note early - Investing.com
Virpax Pharmaceuticals pays off $2.5 million secured note early By Investing.com - Investing.com Canada
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Virpax Pharmaceuticals Inc Azioni (VRPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):